

1 **Immunometabolic Blood Biomarkers of Developmental Trajectories of Depressive**

2 **Symptoms: Findings From the ALSPAC Birth Cohort**

3 Running title: Immunometabolic markers of depression trajectories

4

5 Authors:

Ruby S. M. Tsang <sup>1,2,3</sup>	PhD	<a href="mailto:ruby.tsang@bristol.ac.uk">ruby.tsang@bristol.ac.uk</a>	0000-0002-2520-526X
Daniel Stow <sup>4</sup>	PhD	<a href="mailto:d.stow@qmul.ac.uk">d.stow@qmul.ac.uk</a>	0000-0002-9534-4521
Alex S. F. Kwong <sup>1,5</sup>	PhD	<a href="mailto:akwong@ed.ac.uk">akwong@ed.ac.uk</a>	0000-0003-1953-2771
Nicholas A. Donnelly <sup>1,2,6</sup>	PhD, MRCPsych	<a href="mailto:nick.donnelly@bristol.ac.uk">nick.donnelly@bristol.ac.uk</a>	0000-0003-2234-8545
Holly Fraser <sup>1,2,3</sup>	MSc	<a href="mailto:holly.fraser@bristol.ac.uk">holly.fraser@bristol.ac.uk</a>	0000-0001-9752-0042
Inês A. Barroso <sup>7</sup>	PhD	<a href="mailto:ines.barroso@exeter.ac.uk">ines.barroso@exeter.ac.uk</a>	0000-0001-5800-4520
Peter A. Holmans <sup>8</sup>	PhD	<a href="mailto:holmanspa@cardiff.ac.uk">holmanspa@cardiff.ac.uk</a>	0000-0003-0870-9412
Michael J. Owen <sup>8,9</sup>	PhD, FRCPPsych	<a href="mailto:owenmj@cardiff.ac.uk">owenmj@cardiff.ac.uk</a>	0000-0003-4798-0862
Megan L. Wood <sup>10</sup>	PhD	<a href="mailto:m.l.wood@leeds.ac.uk">m.l.wood@leeds.ac.uk</a>	0000-0003-1882-2355
LINC Consortium*			
Marianne B. M. van den Bree <sup>8,9</sup>	PhD	<a href="mailto:vandenbreemb@cardiff.ac.uk">vandenbreemb@cardiff.ac.uk</a>	0000-0002-4426-3254
Nicholas J. Timpson <sup>1,2</sup>	PhD	<a href="mailto:n.j.timpson@bristol.ac.uk">n.j.timpson@bristol.ac.uk</a>	0000-0002-7141-9189
Golam M. Khandaker <sup>1,2,3,11</sup>	PhD, FRCPPsych	<a href="mailto:golam.khandaker@bristol.ac.uk">golam.khandaker@bristol.ac.uk</a>	0000-0002-4935-9220

6

7 Affiliations:

8 <sup>1</sup> MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK

9 <sup>2</sup> Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK

10 <sup>3</sup> Centre for Academic Mental Health, Population Health Sciences, University of Bristol, Bristol,

11 UK

12 <sup>4</sup> Wolfson Institute of Population Health, Queen Mary University of London, London, UK

13 <sup>5</sup> Division of Psychiatry, University of Edinburgh, Edinburgh, UK

14 <sup>6</sup> Avon and Wiltshire NHS Mental Health Partnership NHS Trust, Bristol, UK

15 <sup>7</sup> Exeter Centre of Excellence for Diabetes Research, University of Exeter, UK

16 <sup>8</sup> Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and  
17 Clinical Neurosciences, Cardiff University, Cardiff, UK

18 <sup>9</sup> Neuroscience and Mental Health Innovation Institute, Division of Psychological Medicine and  
19 Clinical Neurosciences, Cardiff University, Cardiff, UK

20 <sup>10</sup> School of Psychology, University of Leeds, Leeds, UK

21 <sup>11</sup> NIHR Bristol Biomedical Research Centre, Bristol, UK

22 \* A list of members and their affiliations appear at the end of the paper.

23

24 Corresponding author:

25 Dr Ruby Tsang

26 Population Health Sciences, Bristol Medical School

27 Oakfield House, Oakfield Grove

28 Bristol BS8 2BN

29 United Kingdom

30 [ruby.tsang@bristol.ac.uk](mailto:ruby.tsang@bristol.ac.uk)

31

32

33 **Abstract**

34 Studies of longitudinal trends of depressive symptoms in young people could provide insight into  
35 aetiologic mechanism, heterogeneity and origin of common cardiometabolic comorbidities for  
36 depression. Depression is associated with immunological and metabolic alterations, but  
37 immunometabolic characteristics of developmental trajectories of depressive symptoms remain  
38 unclear. Using depressive symptoms scores measured on 10 occasions between ages 10 and 25  
39 years in the Avon Longitudinal Study of Parents and Children (n=7302), we identified four distinct  
40 trajectories: low-stable (70% of the sample), adolescent-limited (13%), adulthood-onset (10%)  
41 and adolescent-persistent (7%). We examined associations of these trajectories with: i)  
42 anthropometric, cardiometabolic and psychiatric phenotypes using multivariable regression  
43 (n=1709-3410); ii) 67 blood immunological proteins and 57 metabolomic features using empirical  
44 Bayes moderated linear models (n=2059 and n=2240 respectively); and iii) 28 blood cell counts  
45 and biochemical measures using multivariable regression (n=2256). Relative to the low-stable  
46 group, risk of depression and anxiety in adulthood was higher for all other groups, especially in  
47 the adolescent-persistent ( $OR_{\text{depression}}=22.80$ , 95% CI 15.25-34.37;  $OR_{\text{GAD}}=19.32$ , 95% CI 12.86-  
48 29.22) and adulthood-onset ( $OR_{\text{depression}}=7.68$ , 95% CI 5.31-11.17;  $OR_{\text{GAD}}=5.39$ , 95% CI 3.65-  
49 7.94) groups. The three depression-related trajectories vary in their immunometabolic profile,  
50 with evidence of little or no alterations in the adolescent-limited group. The adulthood-onset  
51 group shows widespread classical immunometabolic changes (e.g., increased immune cell  
52 counts and insulin resistance), while the adolescent-persistent group is characterised by higher  
53 BMI both in childhood and adulthood with few other immunometabolic changes. These findings  
54 point to distinct mechanisms and intervention opportunities for adverse cardiometabolic profile in  
55 different groups of young people with depression.

56

57

58

## 59 Introduction

60 The first two decades of life represent a critical epoch for human neurodevelopment when most  
61 serious mental illnesses of adult life first emerge.<sup>1</sup> Half of all lifetime cases of common mental  
62 disorders including depression and anxiety start by 14 years and 75% by 24 years.<sup>2</sup> The first  
63 onset of clinically recognised depressive episodes typically occurs between the ages of 12 and  
64 15 years<sup>3</sup> and the increase in new onset of depression peaks between the ages of 15 and 18  
65 years.<sup>4</sup> Depressive symptoms in childhood and adolescence, including those below diagnostic  
66 thresholds, are associated with an elevated risk of depression and other psychiatric diagnoses  
67 subsequently in adulthood.<sup>2, 5-7</sup> These findings highlight the need for studying depressive  
68 symptoms during early life.

69

70 Characterisation of longitudinal profiles of depressive symptoms during development could help  
71 understand the pathogenesis and heterogeneity of later depression, as different individuals may  
72 arrive at the same destination via different routes. There is growing evidence to suggest  
73 characteristic depression trajectories in childhood and adolescence are differentially associated  
74 with risk factors and outcomes. Existing studies have reported associations of a 'high' or  
75 'increasing' depression trajectory with female sex, lower socioeconomic status, stressful life  
76 events, conduct issues, substance use, and parental psychopathology.<sup>3, 8, 9</sup> Trajectories with  
77 higher symptom burden have been associated with subsequent depression and other psychiatric  
78 diagnoses, lower educational attainment, income and poorer psychosocial adjustment.<sup>8-10</sup>  
79 However, less is known about underlying biological correlates of depression trajectories,  
80 including blood-based biomarker signatures. A better understanding of the biological correlates  
81 may help uncover mechanistic insights and identify accessible predictive markers for depression.

82

83 Existing literature suggests that depression and specific symptoms or symptom dimensions of  
84 depression are associated with immunometabolic dysfunction, but there is limited work on  
85 immunometabolic correlates of depression trajectories. Depression is associated with  
86 immunometabolic alterations such as chronic low-grade inflammation,<sup>11, 12</sup> neuroendocrine  
87 dysregulations,<sup>13</sup> as well as less favourable metabolic and lipid profiles.<sup>12, 14</sup> Overall effect sizes

88 for some of these associations are inconsistent, which could be partly due to clinical or  
89 phenotypic heterogeneity within cross-sectional studies.<sup>12</sup> For instance, immunometabolic  
90 alterations appear to be more pronounced or common in individuals endorsing atypical energy-  
91 related symptoms of depression (e.g., hyperphagia, weight gain, hypersomnia, or leaden  
92 paralysis) as opposed to melancholic symptoms.<sup>12, 15</sup> At the symptom level, inflammatory  
93 markers are particularly associated with somatic and neurovegetative symptoms of depression  
94 (e.g., fatigue, altered sleep and appetite) as opposed to psychological symptoms (e.g.,  
95 hopelessness, excessive/inappropriate guilt).<sup>16, 17</sup> Some of these findings are supported by  
96 Mendelian randomization analyses reporting a potentially causal link between inflammatory  
97 markers (e.g., C-reactive protein (CRP) or interleukin 6 (IL-6)) and fatigue, anhedonia, sleep  
98 problems, appetite and psychomotor changes.<sup>18, 19</sup>

99  
100 The accumulation of risk model for chronic diseases posits that cumulative exposures across the  
101 life course result in diverging health trajectories and widening health inequalities as people age.<sup>20</sup>  
102 By characterising depression trajectories, developmental windows when trajectories begin to  
103 diverge can be identified, and we can then examine potential factors driving such divergence and  
104 biological dysregulations linked to subsequent disease risk. By studying the biomarker signatures  
105 of depression trajectories, we may also gain further insight into the origins of higher levels of  
106 cardiometabolic multimorbidity in individuals with depression.<sup>21, 22</sup>

107  
108 The aims of the current study were threefold: (i) to model depression trajectories from childhood  
109 to early adulthood to classify individuals into more homogeneous subgroups, (ii) to examine  
110 associations between these subgroups and risk of psychiatric and cardiometabolic outcomes in  
111 early adulthood, and (iii) to examine associations of these subgroups with clinical and blood  
112 immunometabolic markers including proteomic, metabolomic and biochemical measures in early  
113 adulthood. By examining the broader biomarker signature across different domains including the  
114 immune proteome, metabolome, and clinical biochemistry, we aim to provide more  
115 comprehensive insights into biological pathways and systems possibly involved in the  
116 development and persistence of depressive symptoms in young people.

117

## 118 **Materials and Methods**

### 119 *Description of cohort*

120 This study uses data from the Avon Longitudinal Study of Parents and Children (ALSPAC).  
121 Pregnant women resident in the former county of Avon, United Kingdom (UK) with expected  
122 dates of delivery between 1<sup>st</sup> April 1991 and 31<sup>st</sup> December 1992 were invited to take part in the  
123 ALSPAC study. The initial recruitment enrolled 14541 pregnancies, which resulted in 14062 live  
124 births and 13988 infants still alive at 12 months. Further recruitment of eligible participants took  
125 place when the oldest children were approximately seven years of age; the total sample size for  
126 analyses using any data collected after the age of seven is therefore 15447 pregnancies; of  
127 these, 14901 children were alive at 12 months of age.<sup>23, 24</sup>

128

129 The study website contains details of all the data that is available through a fully searchable data  
130 dictionary and variable search tool: <http://www.bristol.ac.uk/alspac/researchers/our-data/>

131

### 132 *Data*

#### 133 Sociodemographic and health variables

134 Sociodemographic characteristics used to characterise the identified depressive symptom  
135 trajectories include sex, ethnicity, maternal education, maternal occupational social class,  
136 socioeconomic deprivation, and family adversity during pregnancy. Health characteristics  
137 examined include smoking, at-risk drinking, carotid intima-media thickness, carotid-femoral pulse  
138 wave velocity, metabolic syndrome and its components, obesity, and psychiatric outcomes and  
139 medications. Detailed description of these variables as well as those included as covariables in  
140 the biomarker analyses are presented in **Methods S1**.

141

#### 142 Depressive symptoms

143 Self-reported depressive symptoms were assessed using the 13-item Short Mood and Feelings  
144 Questionnaire (SMFQ).<sup>25</sup> We used data collected on 10 occasions between the ages of 10 and  
145 25 years (ages 10, 12, 13, 16, 17, 18, 21, 22, 23, 25), ending with the last questionnaire

146 administered in 2017-2018, prior to the start of the COVID-19 pandemic (see **Table S1**).  
147 Questions were answered based on the two-weeks prior to completing the questionnaire. Each  
148 SMFQ item is scored as 0 = “not true”, 1 = “sometimes true” and 2 = “always true”, resulting in a  
149 total SMFQ sum score 0-26 (higher score reflects more symptoms). For individuals who had  
150 missing data on fewer than three questions, score was imputed to the median value for missing  
151 items. For each time-point, those with missing data on more than three questions had their total  
152 score recoded as missing.

153

154 Circulating blood biomarkers

155 For this analysis, blood biomarkers were assayed in blood samples collected at the face-to-face  
156 research clinic undertaken at 24 years. A total of 92 circulating inflammatory proteins were  
157 measured using the Olink Target 96 Inflammation panel (Olink Analysis Service, Uppsala,  
158 Sweden); proteins with  $\geq 50\%$  values below the limit of detection (LOD) were excluded leaving 67  
159 proteins to be included (**Table S2**). Over 220 metabolomic features (148 metabolites and 77  
160 ratios) were quantified using a high-throughput  $^1\text{H-NMR}$  spectroscopy-based platform  
161 (Nightingale Health, Helsinki, Finland) using a standardised protocol and parameters described  
162 elsewhere.<sup>26-28</sup> Lipoprotein subclasses were excluded from the analysis to minimise redundancy  
163 of information, leaving a subset of 57 metabolomic features (9 cholesterol measures, 12  
164 apolipoproteins and lipids measures, 3 lipoprotein particle sizes, 16 fatty acids and saturation  
165 measures, 3 glycolysis-related metabolites, 8 amino acids, 3 ketone bodies, 2 fluid balance-  
166 related measures and 1 inflammation-related measure) to be included in the analysis (**Table S3**).  
167 All 26 blood count and chemistry measures collected at the same clinic interaction were included  
168 (**Table S4**). Additionally, we computed the aspartate aminotransferase/alanine aminotransferase  
169 (AST/ALT) ratio and the Homeostatic Model Assessment for Insulin Resistance (HOMA-IR).  
170 Further information on data collection and processing of all blood biomarkers are presented in  
171 **Methods S1**.

172

173 Covariables

174 Prior to statistical analysis, we plotted a directed acyclic graph (DAG) showing theoretical  
175 relationships between depression trajectories (independent variable), immunometabolic markers  
176 (dependent variables) and important covariables based on the literature (**Figure S1**). The  
177 minimum adjustment set of confounders included in models was sex at birth, maternal education,  
178 maternal occupational social class, and body mass index (BMI) at age 10.

179

#### 180 *Statistical analysis*

#### 181 Characterisation of depression trajectories

182 Latent class trajectory modelling was performed using the *lcmm* R package<sup>29</sup> to identify  
183 subgroups with distinct SMFQ trajectories. This type of modelling seeks to identify homogenous  
184 groups of individuals with similar trajectories within a heterogeneous population by combining a  
185 latent class model and a mixed model. Models are estimated within the maximum likelihood  
186 framework.<sup>29</sup> The *lcmm* package distinguishes time of measurement and occasion, so individuals  
187 with missing data can still be included; we included those with at least three measurements for  
188 better modelling of non-linear trajectories. A multi-step approach adapted from the model  
189 selection framework suggested by Lennon et al.<sup>30</sup> and van der Nest et al.<sup>31</sup> was used, with the  
190 order of steps changed to address potential overextraction of latent classes from model under-  
191 specification as reported in the simulation literature<sup>32, 33</sup>. The steps followed:

192 1. Scope literature and inspect plots to inform polynomial order and potential number of classes.

193 We modelled  $smfq \sim age + age^2$  and estimated models up to six latent classes.

194 2. Estimate growth mixture models (GMM) with random intercepts and class-specific  
195 proportional random-effect variance-covariance matrix with increasing number of classes.

196 Select the most appropriate number of classes  $k$  based on model convergence, model fit  
197 (Bayesian information criterion (BIC), Integrated Completed Likelihood (ICL), and relative  
198 entropy), smallest class size  $\geq 5\%$  and visual inspection of the trajectories.

199 3. Test alternative model structures with  $k$  classes – GMM with random intercepts and common  
200 random-effect variance-covariance matrix, and group-based trajectory models (GBTM);

201 compare model fit indices, smallest class size and visually inspect trajectories as above, and



202 assess model adequacy (average posterior probabilities  $\geq 0.7$  and odds of correct  
203 classification  $\geq 5$  for all classes).

204 4. Refine trajectory shape by testing up to second-degree fractional polynomials including (-2, -  
205 1, -0.5, 0, 0.5, 1, 2, 3) where 0 refers to  $\log X$  and repeated polynomials refer to  $(X^i + X^i * \log$   
206  $X)$ . Select final model based on model convergence and model fit.

207

208 Age (in years) was used as the time variable in all models. No covariables were included in these  
209 latent class mixed models as the aim is to describe the trajectories; covariables were accounted  
210 for in the next step when testing for associations with phenotypes of interest and biomarkers. For  
211 each model, an automatic grid search with 50 sets of random initial values and up to 10 iterations  
212 was run to reduce the odds of the model converging towards a local maximum and then up to  
213 500 iterations were allowed for the final estimation. Using the selected model, posterior  
214 probabilities for class membership were then estimated and individuals were assigned to the  
215 class of highest posterior probability in the entire sample using the *predictClass* function. We first  
216 performed the latent class mixed modelling on the subsample with three or more data points and  
217 then predicted class membership in the entire sample to reduce uncertainty in the modelling  
218 stage and to maximise sample sizes in the subsequent analyses. Additional information on the  
219 modelling is presented in **Supplementary Methods S1**, R scripts are provided in  
220 **Supplementary Methods S2**. The reporting of this study adheres to the Guidelines for Reporting  
221 on Latent Trajectory Studies (GRoLTS)<sup>34</sup> (**Table S5**).

222

223 Associations with clinical and sociodemographic variables

224 Sociodemographic characteristics are stratified by trajectory class and summarised using mean  
225 (SD), median [interquartile range] or count (%) as appropriate, with differences between  
226 trajectories tested with chi-square or Kruskal-Wallis tests. Associations of trajectory membership  
227 with psychiatric or cardiometabolic outcomes of interest at age 24 or 28 years were tested using  
228 multivariable linear or logistic regressions, using the largest trajectory class as the reference  
229 group and adjusting for sex, maternal education, occupational social class and BMI at age 10.  
230 These variables are described in detailed in **Supplementary Methods S1**.

231

232 Associations with immunometabolic biomarkers

233 For both proteomic and metabolomic data, associations between depression trajectories and

234 markers were evaluated using multiple linear models fitted in the *limma* R package.<sup>35</sup> *Limma*

235 uses an empirical Bayes method to moderate the standard errors of the estimated log-fold

236 changes by borrowing strength from linear models of the other analytes and allowing for different

237 variability between analytes and between samples. Planned contrasts of each of the intermediary

238 trajectories against the trajectory with the most individuals were conducted. With the blood count

239 and clinical chemistry data, linear regressions were fitted with blood markers as dependent

240 variables and SMFQ trajectory class as the independent variable.

241

242 For each of these markers, the basic model included sex, maternal education and maternal

243 occupational social class as covariables and the adjusted model further included BMI at age 10

244 as a covariable. Correction for multiple testing was performed for each set of models using the

245 Benjamini-Hochberg procedure, using a false discovery rate (FDR) q-value threshold of <0.1.

246 This threshold was chosen due to the large number of biomarkers tested, a relatively small

247 sample size and the exploratory nature of this work. R scripts for these analyses are provided in

248 **Supplementary Methods S2.**

249

250 Sensitivity analyses

251 To address potential error carried over from the probabilistic latent class assignment into the

252 association analyses, we performed two sets of sensitivity analyses, the first set by restricting the

253 sample to individuals who had a modal posterior probability  $\geq 0.7$ , and the second set by using

254 the individuals' posterior probabilities for each latent class as separate terms in the models.

255

256 Data extraction and initial data cleaning was performed in StataMP version 17.<sup>36</sup> Further data

257 preparation and statistical analyses were conducted in R versions 4.1.1 and 4.2.1,<sup>37</sup> using

258 packages *tidyverse* (v2.0.0), *lcmm* (v2.0.2), *LCTMtools* (v0.1.3), *tableone* (version 0.13.2), *knitr*

259 (v1.43), *kableExtra* (v1.3.4), *limma* (v3.54.2), and *broom* (v1.0.5). Plots were generated using  
260 *ggplot2* (v3.4.2), *ggpubr* (v0.6.0), and *ggrepel* (v0.9.3).

261

262 Ethical approval

263 Ethical approval for the ALSPAC study was obtained from the ALSPAC Ethics and Law  
264 Committee and the Local Research Ethics Committees. Consent for biological samples has been  
265 collected in accordance with the Human Tissue Act (2004). Informed consent for the use of data  
266 collected via questionnaires and clinics was obtained from participants following the  
267 recommendations of the ALSPAC Ethics and Law Committee at the time.

268

## 269 **Results**

### 270 *Sample*

271 Latent class trajectory modelling was performed on data from 7302 participants who had SMFQ  
272 scores available from at least three time-points between ages 10 and 25 years. Once the best-  
273 fitting model was identified, posterior probabilities and class membership were estimated in the  
274 entire sample, and 9595 individuals were assigned class membership. Of these 9595 individuals,  
275 2256 had sufficient biomarker and complete covariable data to be included in the biomarker  
276 analyses (**Figure S2**).

277

### 278 *Depressive symptom trajectories from childhood to early adulthood*

279 Following comparison of model fit and adequacy statistics and visual inspection of trajectory plots  
280 (**Table S6 and Figures S2-S3**), a four-class group-based trajectory model was identified as best  
281 describing the data. As shown in **Figure 1**, the four identified depressive symptom trajectories  
282 from childhood to early adulthood can be described as follows: low-stable – those who  
283 consistently had no or low levels of depressive symptoms (69.6%, n=6680), adolescent-limited –  
284 those who had elevated depressive symptoms in childhood/adolescence that decreased over  
285 time (13.3%, n=1280), adolescent-persistent – those who had elevated depressive symptoms in  
286 childhood/adolescence that remained high into adulthood (7.0%, n=672) and adulthood-onset –

287 those who started with low levels of depressive symptoms that increased in late  
288 adolescence/early adulthood (10.0%, n=973).

289

290 *Characteristics of depression trajectories*

291 Descriptive statistics for characteristics of these individuals, stratified by trajectory, are presented  
292 in **Table 1** below. There were more women in all three depression-related trajectories:  
293 adolescent-limited (66.3%), adolescent-persistent (76.5%), and adulthood-onset trajectories  
294 (64.6%). Additionally, the adolescent-persistent trajectory was associated with lower maternal  
295 education and greater family adversity during pregnancy. Descriptive statistics for the same  
296 characteristics of the subset of individuals who were included in the biomarker analyses are  
297 presented in **Table S7**.

298

299 [INSERT FIGURE 1 HERE]

300 **Table 1. Characteristics of depressive symptom trajectories in the ALSPAC birth cohort.**

	Low-stable (n=6680)	Adolescent- limited (n=1280)	Adolescent- persistent (n=672)	Adulthood- onset (n=963)	<i>p</i>
Sex: Female	3064 (45.9%)	849 (66.3%)	514 (76.5%)	622 (64.6%)	<0.001
Ethnicity: Non-white	240 (4.1%)	44 (3.9%)	36 (6.2%)	40 (4.8%)	0.097
Maternal education					0.026
CSE or none	894 (15.1%)	159 (13.9%)	107 (17.9%)	120 (14.1%)	
Vocational	560 (9.5%)	91 (8.0%)	53 (8.9%)	64 (7.5%)	
O-level	2064 (34.9%)	406 (35.6%)	231 (38.6%)	293 (34.5%)	
A-level	1483 (25.1%)	308 (27.0%)	141 (23.6%)	230 (27.1%)	
Degree	911 (15.4%)	178 (15.6%)	66 (11.0%)	142 (16.7%)	
Maternal occupational social class					0.556
I – highest	356 (7.0%)	63 (6.6%)	28 (5.5%)	45 (6.3%)	
II	1714 (33.8%)	335 (35.0%)	161 (31.8%)	250 (34.9%)	
III (non-manual)	2137 (42.2%)	392 (41.0%)	216 (42.7%)	302 (42.1%)	
III (manual)	350 (6.9%)	66 (6.9%)	34 (6.7%)	57 (7.9%)	
IV or V <sup>1</sup> – lowest	509 (10.0%)	100 (10.5%)	67 (13.2%)	63 (8.8%)	
English IMD 2000 quintile					0.723
1 – least deprived	1665 (32.1%)	355 (35.3%)	146 (30.7%)	242 (33.3%)	
2	1044 (20.1%)	188 (18.7%)	100 (21.0%)	143 (19.7%)	
3	956 (18.4%)	174 (17.3%)	84 (17.6%)	140 (19.3%)	
4	790 (15.2%)	153 (15.2%)	77 (16.2%)	115 (15.8%)	
5 – most deprived	739 (14.2%)	137 (13.6%)	69 (14.5%)	86 (11.8%)	
Family Adversity Index	1 [0, 2]	1 [0, 2]	1 [0, 3]	1 [0, 2]	<0.001
BMI at age 10	17.43 [15.97, 19.73]	17.63 [16.07, 19.96]	18.25 [16.24, 21.00]	17.43 [15.92, 19.60]	<0.001
Number of SMFQ measurements	4 [2, 7]	6 [3, 8]	5 [3, 7]	6 [4, 9]	<0.001

301 <sup>1</sup> Categories have been collapsed due to small cell counts in subsequent analyses.

302 Notes: Numbers presented as mean (SD), median [IQR], or n (%). Percentages are column percentages and  
303 computed based on the number of individuals with available data on each variable. Group comparisons were  
304 conducted using Chi-square tests for categorical variables and Kruskal-Wallis tests for non-normal continuous  
305 variables.

306 Abbreviations: BMI – body mass index; CSE – Certificate of Secondary Education; O-level – Ordinary level; A-  
307 level – Advanced level; IMD – Index of Multiple Deprivation; SMFQ – Short Mood and Feelings Questionnaire  
308

309 **Table 2. Associations of depressive symptom trajectories with anthropometric and cardiometabolic**  
 310 **outcomes at 24 years and psychiatric outcomes at 24 and 28 years**

		Adolescent-limited	Adolescent- persistent	Adulthood-onset
<b>Outcomes assessed at age 24</b>	n	Adjusted unstandardised regression coefficient (SE)		
cIMT (continuous)	1565	-0.0002 (0.0033)	-0.0099 (0.0050)	-0.0003 (0.0036)
cfPWV (continuous)	1708	-0.0578 (0.0708)	-0.1429 (0.1109)	0.0108 (0.0790)
		Adjusted odds ratio (95% CI)		
Smoking	2731	<b>1.66 (1.32-2.09)</b>	<b>2.66 (1.93-3.67)</b>	<b>1.70 (1.32-2.17)</b>
AUDIT-C score ≥ 5	2704	0.97 (0.79-1.21)	<b>0.65 (0.48-0.89)</b>	0.79 (0.63-1.01)
BMI ≥ 30kg/m <sup>2</sup>	2731	1.41 (0.99-2.01)	<b>1.93 (1.19-3.06)</b>	1.34 (0.89-1.99)
Elevated waist circumference	2707	1.21 (0.93-1.56)	1.24 (0.84-1.80)	1.16 (0.86-1.54)
Triglycerides ≥1.7mmol/L	2241	1.37 (0.86-2.11)	1.14 (0.53-2.23)	1.50 (0.93-2.33)
HDL <1.0mmol/L	2241	0.86 (0.61-1.20)	1.13 (0.71-1.77)	1.34 (0.95-1.85)
SBP ≥ 130mmHg	2751	0.85 (0.58-1.22)	0.60 (0.29-1.12)	0.96 (0.65-1.38)
DBP ≥ 85mmHg	2751	1.32 (0.69-2.69)	0.73 (0.17-2.21)	1.32 (0.55-2.82)
Fasting glucose ≥5.6mmol/L	2241	0.86 (0.65-1.14)	0.92 (0.58-1.42)	0.97 (0.72-1.31)
Metabolic syndrome	2759	0.97 (0.59-1.55)	0.78 (0.35-1.54)	1.23 (0.75-1.96)
ICD-10 depressive episode	2729	<b>4.03 (2.73-5.95)</b>	<b>22.80 (15.25-34.37)</b>	<b>7.68 (5.31-11.17)</b>
ICD-10 GAD	2719	<b>3.59 (2.41-5.33)</b>	<b>19.32 (12.86-29.22)</b>	<b>5.39 (3.65-7.94)</b>
<b>Outcomes assessed at age 28</b>				
Prescribed antidepressants in past 5y	2792	<b>3.02 (2.28-3.99)</b>	<b>7.29 (5.22-10.17)</b>	<b>5.12 (3.88-6.75)</b>
Prescribed anxiolytics in past 5y	2828	<b>2.31 (1.25-4.16)</b>	<b>6.76 (3.74-12.05)</b>	<b>4.16 (2.39-7.18)</b>

311  
 312 Notes: Regression models were adjusted for sex, maternal education, maternal occupational social class, and  
 313 BMI at age 10. Effect estimates presented are unstandardised regression coefficients for continuous outcomes  
 314 and odds ratios (95% confidence intervals) for binary outcomes. The reference group for all analyses is the low-  
 315 stable trajectory. Text in bold indicates evidence for the association after FDR correction of p-values.  
 316 Metabolic syndrome was defined based on the 2009 consensus definition from the International Diabetes  
 317 Federation and the American Heart Association/National Heart, Lung, and Blood Institute, i.e. the presence of any  
 318 three of the following five risk factors: elevated waist circumference (≥94cm for white men, ≥90cm for non-white  
 319 men, ≥80cm for women); elevated triglycerides (≥1.7mmol/L), reduced high-density lipoprotein-cholesterol

320 (<1.0mmol/L), elevated blood pressure (systolic  $\geq$ 130mmHg or diastolic  $\geq$ 85mmHg), and elevated fasting glucose  
321 ( $\geq$ 5.6mmol/L).  
322 Abbreviations: AUDIT-C – Alcohol Use Disorders Identification Test for Consumption; BMI – body mass index;  
323 cfPWV – carotid-femoral pulse wave velocity; cIMT – carotid intima-media thickness; DBP – diastolic blood  
324 pressure; GAD – generalised anxiety disorder; HDL – high-density lipoprotein; ICD-10 – International  
325 Classification of Diseases 10<sup>th</sup> Revision; SBP – systolic blood pressure  
326  
327  
328



329 *Adulthood cardiometabolic and psychiatric outcomes associated with depression trajectories*

330 Compared to the low-stable trajectory, after adjusting for sex, maternal education, maternal  
331 occupational class and BMI at age 10, all three depression-related trajectories were associated  
332 with ICD-10 diagnosis of depression, generalised anxiety disorder, being prescribed an  
333 antidepressant or anxiolytic at ages 24 and 28 years. However, the magnitude of association  
334 varied between the trajectories, with the risk for these outcomes being the highest for the  
335 adolescent-persistent trajectory (approximately 20-fold risk), followed by the adulthood-onset and  
336 adolescent-limited trajectories. The adolescent-persistent trajectory was additionally associated  
337 with obesity (**Table 2**). Unadjusted model results are presented in **Table S8**.

338

339 *Differentially abundant proteins associated with depression trajectories*

340 Relative to the low-stable trajectory, after adjusting for sex, maternal education, maternal  
341 occupational class and BMI at age 10, one protein (C-C motif chemokine 25 [CCL25]) was  
342 upregulated in the adolescent-limited trajectory; four proteins (fibroblast growth factor 21 [FGF-  
343 21], hepatocyte growth factor [HGF], eukaryotic translation initiation factor [4E-BP1], and eotaxin-  
344 1 [CCL11]) were upregulated in the adolescent-persistent trajectory; and five proteins (FGF-21,  
345 fibroblast growth factor 19 [FGF-19], CUB domain-containing protein 1 [CDCP1], HGF, CCL11)  
346 were upregulated in the adulthood-onset trajectory (**Figure 2**). Full model results are presented  
347 in **Tables S9-10**.

348

349 *Differentially abundant metabolites associated with depressive symptom trajectories*

350 Relative to the low-stable trajectory, after adjusting for sex, maternal education and occupational  
351 class, and BMI at age 10, creatinine was decreased in the adolescent-persistent trajectory. Three  
352 metabolite ratios (omega-3 to total fatty acids [ $\omega$ -3/FA], docosahexaenoic acid to total fatty  
353 acids [DHA/FA], polyunsaturated fatty acids to total fatty acids [PUFA/FA] ratios) were decreased  
354 whereas the monosaturated to total fatty acids (MUFA/FA) and apolipoprotein B to apolipoprotein  
355 A1 (ApoB/ApoA1) ratios were increased in the adult-onset trajectory (**Figure 3**). Full model  
356 results are presented in **Tables S11-12**.

357

358 *Blood count and clinical chemistry markers*

359 Relative to the low-stable trajectory, after adjusting for sex, maternal education and occupational  
360 class, and BMI at age 10, there was evidence for decreased AST levels in the adolescent-limited  
361 trajectory, and increased HOMA-IR, insulin, neutrophil and white blood cell (WBC) counts in the  
362 adulthood-onset trajectory (**Figure 5**). Full model results are presented in **Tables S13-14**.

363

364 *Sensitivity analyses*

365 The sensitivity analyses showed patterns of associations that are largely similar to those  
366 observed in the primary analyses, with consistent associations of depression-related trajectories  
367 with anthropometric, cardiometabolic and psychiatric outcomes, and top-ranking  
368 immunometabolic biomarkers with similar effect sizes in the same directions (**Supplementary**  
369 **Methods S3**).

370

371 [INSERT FIGURES 2-4 HERE]

372

373 **Discussion**

374 Depression is a complex heterogeneous disorder, which poses a challenge for discovering  
375 biomarkers associated with disease onset and/or progression. We have taken a longitudinal  
376 approach to identifying blood-based biomarkers for depression by examining longitudinal  
377 patterns of depressive symptoms in the population during the critical developmental epoch of  
378 childhood, adolescence and early adulthood. Using data from a prospective birth cohort, we have  
379 identified four longitudinal population subgroups based on repeated measures of depressive  
380 symptoms over a 15-year period from ages 10 to 25 years. We show that majority of participants  
381 (approximately 70%) have little or no depressive symptoms (low-stable group). We identified  
382 three depression-related groups which comprise a group with higher symptom levels during  
383 childhood and adolescence which later decrease (adolescent limited group, 13%), a group with  
384 symptoms emerging during puberty which persist throughout adolescence through to adulthood  
385 (adolescent persistent group, 7%), and a group with symptoms emerging during late  
386 adolescence/early adulthood and increasing thereafter (adulthood onset, 10%).

387

388 We have examined health phenotypes and blood biomarkers associated with these subgroups  
389 for greater insight into the developmental course of depression and associated biomarkers. Our  
390 analyses show that compared to the low-stable group, risk of depression and anxiety in  
391 adulthood is higher for all three depression-related groups. However, such risk is particularly  
392 elevated risk for the adolescent-persistent group (19 to 23-fold risk) followed by the adulthood-  
393 onset group (five to eight-fold risk). Interestingly, the group where higher levels of symptoms are  
394 mostly limited to adolescence, they still have a three-fold increased risk of depression in  
395 adulthood.

396

397 Having examined health phenotypic and blood proteomic, immunological and metabolic  
398 biomarker associations for these three groups, we show that the adolescent-limited group is  
399 distinct from the other two depression-related groups as it showed little immunometabolic  
400 alterations. In contrast, both the adolescent-persistent and adulthood-onset groups are  
401 associated with immunometabolic changes, but the exact pattern of associations varies between  
402 the two groups. The adolescent-persistent group was associated with higher BMI in childhood  
403 and adulthood, whereas the adulthood-onset group did not show this, but rather more  
404 widespread alterations in blood-based metabolic parameters including insulin resistance, insulin  
405 levels and changes in fatty acid ratios. Blood proteomic changes were largely similar between  
406 the two groups and involved proteins that mainly act as growth factors, cytokines and  
407 chemokines. While immunometabolic associations persisted given adjustment for childhood BMI  
408 in the adolescent-persistent group, the presence or absence of this BMI adjustment had an  
409 impact on some association estimates in the adolescent-persistent and adulthood-onset groups.  
410 While this may relate to the apparent differences in BMI by trajectories, it is difficult to distinguish  
411 this as an artefact of adjustment or a true impact of BMI.

412

413 Epidemiological studies consistently report a bidirectional relationship (both cross-sectionally and  
414 longitudinally) between obesity and depression,<sup>38</sup> whereas Mendelian randomization studies  
415 support a causal role of BMI on major depressive disorder and depressive symptoms but not vice

416 versa.<sup>39, 40</sup> The comorbidity between obesity and depression is generally associated with poorer  
417 prognosis, with studies reporting associations with a more chronic course of depression in  
418 adulthood<sup>41, 42</sup> as well as poorer treatment response.<sup>43</sup> Our findings add to this evidence by  
419 showing an association between higher childhood BMI and persistent depressive symptoms  
420 between adolescence and early adulthood.

421

422 Many of the alterations observed in the adulthood-onset trajectory are already well studied  
423 markers of cardiometabolic disease risk. The ApoB/ApoA1 ratio is associated with cardiovascular  
424 diseases and metabolic syndrome,<sup>44, 45</sup> and can be used to predict longer-term cardiovascular  
425 risk when measured in early life.<sup>46, 47</sup> Higher values of HOMA-IR are associated with an  
426 increased risk of developing type 2 diabetes mellitus (T2DM), systemic arterial hypertension and  
427 non-fatal major adverse cardiovascular events.<sup>48</sup> Lower blood omega-3 fatty acid concentrations  
428 are associated with poorer cardiovascular outcomes<sup>49, 50</sup> and may also contribute to chronic  
429 systemic inflammation, whereas changes in MUFA, PUFA and DHA concentrations in early  
430 adulthood were associated with incident obesity, insulin resistance and elevated blood pressure  
431 10 years later.<sup>51</sup> Since dietary intake and supplementation are the main predictors of blood levels  
432 of omega-3 fatty acids,<sup>52, 53</sup> with lifestyle factors such as BMI, smoking and alcohol consumption  
433 also playing a role,<sup>54</sup> this suggests that the adulthood-onset group may benefit from lifestyle  
434 intervention to prevent future cardiometabolic disease.

435

436 The overlapping proteomic signals observed between the adolescent-persistent and adulthood-  
437 onset trajectories potentially suggest shared underlying mechanisms (genetic or environmental)  
438 or shared biological responses to depression, which warrant further study for their roles in the  
439 pathophysiology of depression and cardiometabolic disease. FGF-21 is a novel regulator of  
440 glucose and lipid metabolism that mainly acts through an FGF receptor 1 (FGFR1)/ $\beta$ -klotho  
441 receptor complex and the Ras/Raf MAPK signalling pathway, which have been implicated in the  
442 pathophysiology of depression and therapeutic effects of antidepressants.<sup>55-57</sup> Elevated  
443 circulating FGF-21 concentrations have also been shown to be associated with a range of  
444 cardiometabolic markers and diseases.<sup>58-62</sup> HGF mediates inflammatory responses to tissue

445 injury and regulates cell growth and morphogenesis through the activation of the  
446 HGF/mesenchymal-epithelial transition factor (c-Met) signalling pathway, which has downstream  
447 effects on the Raf/MAPK and PI3K/Akt pathways. Altered HGF/c-Met signalling has been  
448 suggested to play a role in the pathogenesis of depression in adolescents through disrupting  
449 interneuron development.<sup>63</sup> CCL11 is a chemokine involved in the selective recruitment of  
450 eosinophils into sites of inflammation and has been implicated in various allergic and  
451 inflammatory conditions.<sup>64</sup> It can be transported across the blood-brain barrier<sup>65</sup> and is an age-  
452 related systemic factor associated with reduced synaptic plasticity and impaired hippocampal-  
453 dependent learning and memory in mice.<sup>66</sup> In humans, CCL11 levels increase with age,<sup>66</sup> and  
454 there is emerging evidence to suggest that CCL11 levels are associated with psychiatric  
455 disorders.<sup>67-71</sup> In summary, the overlapping proteomic signals between the adolescent-persistent  
456 and adulthood-onset trajectories highlight potential roles of physiological stress from lifestyle or  
457 environmental factors, disruptions in neurodevelopment, and neurogenesis and cellular  
458 senescence in the underlying vulnerability or biological response to depression, and may be key  
459 biomarkers relevant to illness pathogenesis.

460

461 An advantage of our work is that by examining depressive symptoms longitudinally using a latent  
462 class trajectory approach, we can account for population heterogeneity and obtain better  
463 characterisation of subgroups and their changes over time. Existing literature shows that  
464 depression is associated with alterations in various immunometabolic biomarkers, including  
465 increased inflammatory cytokines,<sup>72,73</sup> WBC,<sup>74</sup> neutrophils,<sup>74</sup> T-lymphocytes and other immune  
466 cell counts,<sup>74</sup> HOMA-IR,<sup>75</sup> insulin,<sup>75</sup> lipids and fatty acids.<sup>76,77</sup> Using longitudinal data from young  
467 people, we add to this evidence base by showing that classical immunometabolic changes are  
468 particularly associated with an adulthood-onset trajectory, rather than other developmental  
469 subgroups of depressive symptoms, including one with persistent symptoms since adolescence.

470

471 This study has several limitations. Firstly, the approach of treating assigned class membership as  
472 discrete in assessing relationships with other variables has been shown to underestimate the  
473 strength of the relationships.<sup>78</sup> However, as we are mainly interested in subpopulations with

474 different depressive symptom trajectories, this approach allows for easier interpretation and  
475 translation. Secondly, depression is episodic in nature and the use of polynomials cannot fully  
476 capture the dynamics of depressive symptom severity over time; however, this approach was  
477 chosen over other methods (e.g., splines) for model parsimony.

478

479 Furthermore, the sample size in this study is relatively small and may be underpowered to detect  
480 differences after stratifying individuals into four separate trajectories. For this reason, we did not  
481 further stratify our analyses by sex or potentially relevant variables (e.g., BMI). While we have  
482 adjusted our biomarker analyses for several potential confounders, residual confounding could  
483 still be an issue. For instance, we have not accounted for medication use or chronic disease etc.,  
484 but these are likely to be uncommon in young people. As the biomarkers were measured at age  
485 24, which is after the onset of depressive symptoms in many individuals, further research is  
486 required to assess the direction and causality of associations we have identified.

487

488 In conclusion, we identified distinct developmental trajectories of depression from childhood to  
489 early adulthood, which show differential associations with cardiometabolic and psychiatric  
490 outcomes, and are characterised by distinct immunometabolic profiles. In particular, individuals  
491 with persistent depressive symptoms from childhood through to early adulthood were more likely  
492 to have higher BMI both in childhood and in adulthood and few other immunometabolic changes,  
493 whereas individuals who develop depressive symptoms towards early adulthood show classical  
494 immunometabolic alterations in immune cell counts, insulin resistance and fatty acid profiles.  
495 These findings point to distinct mechanisms and intervention opportunities for different groups of  
496 young people with depressive symptoms.

## 497 **Acknowledgements**

498 We are extremely grateful to all the families who took part in this study, the midwives for their  
499 help in recruiting them, and the whole ALSPAC team, which includes interviewers, computer and  
500 laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists  
501 and nurses. We would also like to thank members of the LINC study public advisory group for  
502 their contribution.

503

504 This work was funded by the Tackling Multimorbidity at Scale Strategic Priorities Fund  
505 programme (MR/W014416/1) delivered by the UK Medical Research Council (MRC) and the UK  
506 National Institute for Health Research (NIHR) in partnership with the UK Economic and Social  
507 Research Council and in collaboration with the UK Engineering and Physical Sciences Research  
508 Council. RSMT, DS and MLW are supported by this grant. ASFK is supported by a Wellcome  
509 Early Career Award (227063/Z/23/Z). NAD was supported by an NIHR Clinical Lectureship in  
510 General Adult Psychiatry. MBMvdB acknowledges additional funding support from the MRC  
511 (MR/W028395/1, MR/W020297/1, MR/T033045/1 and MR/S037667/1), NIMH (U01MH119758),  
512 the Wellcome Trust (226709/Z/22/Z) and Welsh Government (HS 22 04). NJT is a director of the  
513 MRC/ESRC/UKRI supported Population Research UK Coordination Hub (ES/Y008340/1),  
514 supported by a Wellcome Trust Investigator award (202802/Z/16/Z), is the PI of the Avon  
515 Longitudinal Study of Parents and Children (MRC & WT 217065/Z/19/Z), is supported by the  
516 University of Bristol NIHR Biomedical Research Centre (BRC-1215-2001), the MRC Integrative  
517 Epidemiology Unit (MC\_UU\_00011/1), CRUK and works within the CRUK Integrative Cancer  
518 Epidemiology Programme (C18281/A29019) and with support from CRUK (PRCPJT-  
519 May22\100028). GMK acknowledges funding support from the MRC (MC\_UU\_00032/06), which  
520 forms part of the MRC Integrative Epidemiology Unit at the University of Bristol. This grant also  
521 supports HF. GMK acknowledges additional funding from the Wellcome Trust (201486/Z/16/Z  
522 and 201486/B/16/Z), the MRC (MR/W014416/1; MR/S037675/1; and MR/Z50354X/1), and the  
523 NIHR Bristol Biomedical Research Centre (NIHR 203315). The views expressed are those of the  
524 authors and not necessarily those of the UK NIHR or the Department of Health and Social Care.

525

526 The UK MRC and Wellcome (217065/Z/19/Z) and the University of Bristol provide core support  
527 for ALSPAC. This publication is the work of the authors and RSMT, NJT and GMK will serve as  
528 guarantors for the contents of this paper. A comprehensive list of grants funding is available on  
529 the ALSPAC website ([http://www.bristol.ac.uk/alspac/external/documents/grant-  
530 acknowledgements.pdf](http://www.bristol.ac.uk/alspac/external/documents/grant-acknowledgements.pdf)).

531

532 LINC Consortium members:

533 Marianne B. M. van den Bree, George Kirov, Michael J. Owen, James T. R. Walters, Peter A.

534 Holmans, Jane Lynch, Ioanna K. Katzourou, Nabila Ali, Lowri O'Donovan (Cardiff University, UK)

535 David A. van Heel, Sarah Finer, Daniel Stow (Queen Mary University of London, UK)

536 Golam M. Khandaker, Nicholas J. Timpson, John A. A. Macleod, Julie P. Clayton, Ruby S. M.

537 Tsang, Jane Sprackman, Shahid Khan (University of Bristol, UK)

538 Inês A. Barroso, Rupert A. Payne (University of Exeter, UK)

539 Mark Mon-Williams, Megan L. Wood (University of Leeds, UK)

540 Hilary C. Martin (Wellcome Sanger Institute, UK)

541 Thomas Werge, Andrés Ingason, Morteza Vaez, Lam O. Huang (Institute of Biological Psychiatry,  
542 Denmark)

543

544 **Conflict of Interest**

545 None



546 **References**

- 547 1. Solmi M, Radua J, Olivola M, Croce E, Soardo L, Salazar de Pablo G *et al.* Age at onset of  
548 mental disorders worldwide: large-scale meta-analysis of 192 epidemiological studies.  
549 *Molecular Psychiatry* 2022; **27**(1): 281-295.
- 550
- 551 2. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime  
552 Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National  
553 Comorbidity Survey Replication. *Archives of General Psychiatry* 2005; **62**(6): 593-602.
- 554
- 555 3. Shore L, Toumbourou JW, Lewis AJ, Kremer P. Review: Longitudinal trajectories of child  
556 and adolescent depressive symptoms and their predictors – a systematic review and meta-  
557 analysis. *Child and Adolescent Mental Health* 2018; **23**(2): 107-120.
- 558
- 559 4. Hankin BL, Abramson LY, Moffitt TE, Silva PA, McGee R, Angell KE. Development of  
560 depression from preadolescence to young adulthood: emerging gender differences in a 10-  
561 year longitudinal study. *J Abnorm Psychol* 1998; **107**(1): 128-140.
- 562
- 563 5. Copeland WE, Adair CE, Smetanin P, Stiff D, Briante C, Colman I *et al.* Diagnostic  
564 transitions from childhood to adolescence to early adulthood. *Journal of Child Psychology*  
565 *and Psychiatry* 2013; **54**(7): 791-799.
- 566
- 567 6. Fergusson DM, Woodward LJ. Mental Health, Educational, and Social Role Outcomes of  
568 Adolescents With Depression. *Archives of General Psychiatry* 2002; **59**(3): 225-231.
- 569
- 570 7. Georgiades K, Lewinsohn PM, Monroe SM, Seeley JR. Major Depressive Disorder in  
571 Adolescence: The Role of Subthreshold Symptoms. *Journal of the American Academy of*  
572 *Child & Adolescent Psychiatry* 2006; **45**(8): 936-944.

573

574 8. Yaroslavsky I, Pettit JW, Lewinsohn PM, Seeley JR, Roberts RE. Heterogeneous  
575 trajectories of depressive symptoms: Adolescent predictors and adult outcomes. *Journal of*  
576 *Affective Disorders* 2013; **148**(2): 391-399.

577

578 9. Musliner KL, Munk-Olsen T, Eaton WW, Zandi PP. Heterogeneity in long-term trajectories  
579 of depressive symptoms: Patterns, predictors and outcomes. *Journal of Affective Disorders*  
580 2016; **192**: 199-211.

581

582 10. Weavers B, Heron J, Thapar AK, Stephens A, Lennon J, Bevan Jones R *et al.* The  
583 antecedents and outcomes of persistent and remitting adolescent depressive symptom  
584 trajectories: a longitudinal, population-based English study. *The Lancet Psychiatry* 2021;  
585 **8**(12): 1053-1061.

586

587 11. Khandaker GM, Dantzer R, Jones PB. Immunopsychiatry: important facts. *Psychological*  
588 *Medicine* 2017; **47**(13): 2229-2237.

589

590 12. Milaneschi Y, Lamers F, Berk M, Penninx BWJH. Depression Heterogeneity and Its  
591 Biological Underpinnings: Toward Immunometabolic Depression. *Biological Psychiatry*  
592 2020; **88**(5): 369-380.

593

594 13. Nikkheslat N, Pariante CM, Zunszain PA. Chapter 3 - Neuroendocrine Abnormalities in  
595 Major Depression: An Insight Into Glucocorticoids, Cytokines, and the Kynurenine Pathway.  
596 In: Baune BT (ed). *Inflammation and Immunity in Depression*. Academic Press 2018, pp 45-  
597 60.

598

- 599 14. Bot M, Milaneschi Y, Al-Shehri T, Amin N, Garmaeva S, Onderwater GLJ *et al.*  
600 Metabolomics Profile in Depression: A Pooled Analysis of 230 Metabolic Markers in 5283  
601 Cases With Depression and 10,145 Controls. *Biological Psychiatry* 2020; **87**(5): 409-418.  
602
- 603 15. Lamers F, Milaneschi Y, Vinkers CH, Schoevers RA, Giltay EJ, Penninx BWJH. Depression  
604 profilers and immuno-metabolic dysregulation: Longitudinal results from the NESDA study.  
605 *Brain, Behavior, and Immunity* 2020; **88**: 174-183.  
606
- 607 16. Milaneschi Y, Kappelmann N, Ye Z, Lamers F, Moser S, Jones PB *et al.* Association of  
608 inflammation with depression and anxiety: evidence for symptom-specificity and potential  
609 causality from UK Biobank and NESDA cohorts. *Molecular Psychiatry* 2021; **26**(12): 7393-  
610 7402.  
611
- 612 17. Frank P, Jokela M, Batty GD, Cadar D, Steptoe A, Kivimäki M. Association Between  
613 Systemic Inflammation and Individual Symptoms of Depression: A Pooled Analysis of 15  
614 Population-Based Cohort Studies. *American Journal of Psychiatry* 2021; **178**(12): 1107-  
615 1118.  
616
- 617 18. Kappelmann N, Arloth J, Georgakis MK, Czamara D, Rost N, Ligthart S *et al.* Dissecting  
618 the Association Between Inflammation, Metabolic Dysregulation, and Specific Depressive  
619 Symptoms: A Genetic Correlation and 2-Sample Mendelian Randomization Study. *JAMA*  
620 *Psychiatry* 2021; **78**(2): 161-170.  
621
- 622 19. Pistis G, Milaneschi Y, Vandeleur CL, Lasserre AM, Penninx BWJH, Lamers F *et al.*  
623 Obesity and atypical depression symptoms: findings from Mendelian randomization in two  
624 European cohorts. *Translational Psychiatry* 2021; **11**(1): 96.  
625

- 626 20. Ben-Shlomo Y, Kuh D. A life course approach to chronic disease epidemiology: conceptual  
627 models, empirical challenges and interdisciplinary perspectives. *International Journal of*  
628 *Epidemiology* 2002; **31**(2): 285-293.
- 629
- 630 21. Ditmars HL, Logue MW, Toomey R, McKenzie RE, Franz CE, Panizzon MS *et al.*  
631 Associations between depression and cardiometabolic health: A 27-year longitudinal study.  
632 *Psychological Medicine* 2022; **52**(14): 3007-3017.
- 633
- 634 22. Harshfield EL, Pennells L, Schwartz JE, Willeit P, Kaptoge S, Bell S *et al.* Association  
635 Between Depressive Symptoms and Incident Cardiovascular Diseases. *JAMA* 2020;  
636 **324**(23): 2396-2405.
- 637
- 638 23. Boyd A, Golding J, Macleod J, Lawlor DA, Fraser A, Henderson J *et al.* Cohort Profile: The  
639 'Children of the 90s'—the index offspring of the Avon Longitudinal Study of Parents and  
640 Children. *International Journal of Epidemiology* 2013; **42**(1): 111-127.
- 641
- 642 24. Northstone K, Lewcock M, Groom A, Boyd A, Macleod J, Timpson N, Wells N. The Avon  
643 Longitudinal Study of Parents and Children (ALSPAC): an update on the enrolled sample  
644 of index children in 2019 [version 1; peer review: 2 approved]. *Wellcome Open Research*  
645 2019; **4**(51).
- 646
- 647 25. Angold A, Costello EJ, Messer SC, Pickles A. Development of a short questionnaire for use  
648 in epidemiological studies of depression in children and adolescents. *International Journal*  
649 *of Methods in Psychiatric Research* 1995; **5**(4): 237-249.
- 650

- 651 26. Soininen P, Kangas AJ, Würtz P, Tukiainen T, Tynkkynen T, Laatikainen R *et al.* High-  
652 throughput serum NMR metabonomics for cost-effective holistic studies on systemic  
653 metabolism. *Analyst* 2009; **134**(9): 1781-1785.
- 654
- 655 27. Inouye M, Kettunen J, Soininen P, Silander K, Ripatti S, Kumpula LS *et al.* Metabonomic,  
656 transcriptomic, and genomic variation of a population cohort. *Molecular Systems Biology*  
657 2010; **6**(1): 441.
- 658
- 659 28. Soininen P, Kangas AJ, Würtz P, Suna T, Ala-Korpela M. Quantitative Serum Nuclear  
660 Magnetic Resonance Metabolomics in Cardiovascular Epidemiology and Genetics.  
661 *Circulation: Cardiovascular Genetics* 2015; **8**(1): 192-206.
- 662
- 663 29. Proust-Lima C, Philipps V, Liquet B. Estimation of Extended Mixed Models Using Latent  
664 Classes and Latent Processes: The R Package lcmm. *Journal of Statistical Software* 2017;  
665 **78**(2): 1 - 56.
- 666
- 667 30. Lennon H, Kelly S, Sperrin M, Buchan I, Cross AJ, Leitzmann M *et al.* Framework to  
668 construct and interpret latent class trajectory modelling. *BMJ Open* 2018; **8**(7): e020683.
- 669
- 670 31. van der Nest G, Lima Passos V, Candel MJJM, van Breukelen GJP. An overview of mixture  
671 modelling for latent evolutions in longitudinal data: Modelling approaches, fit statistics and  
672 software. *Advances in Life Course Research* 2020; **43**: 100323.
- 673
- 674 32. van der Nest G, Lima Passos V, Candel MJJM, van Breukelen GJP. Model fit criteria curve  
675 behaviour in class enumeration – a diagnostic tool for model (mis)specification in  
676 longitudinal mixture modelling. *Journal of Statistical Computation and Simulation* 2022;  
677 **92**(8): 1640-1672.

678

679 33. Diallo TMO, Morin AJS, Lu H. Impact of Misspecifications of the Latent Variance–  
680 Covariance and Residual Matrices on the Class Enumeration Accuracy of Growth Mixture  
681 Models. *Structural Equation Modeling: A Multidisciplinary Journal* 2016; **23**(4): 507-531.

682

683 34. van de Schoot R, Sijbrandij M, Winter SD, Depaoli S, Vermunt JK. The GRoLTS-Checklist:  
684 Guidelines for Reporting on Latent Trajectory Studies. *Structural Equation Modeling: A  
685 Multidisciplinary Journal* 2017; **24**(3): 451-467.

686

687 35. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. limma powers differential  
688 expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Research*  
689 2015; **43**(7): e47-e47.

690

691 36. StataCorp. Stata Statistical Software: Release 17. StataCorp LLC: College Station, TX,  
692 USA, 2021.

693

694 37. R Core Team. R: A language and environment for statistical computing. R Foundation for  
695 Statistical Computing: Vienna, Austria, 2022. <https://www.R-project.org/>.

696

697 38. Milaneschi Y, Simmons WK, van Rossum EFC, Penninx BWJH. Depression and obesity:  
698 evidence of shared biological mechanisms. *Molecular Psychiatry* 2019; **24**(1): 18-33.

699

700 39. Hartwig FP, Bowden J, Loret de Mola C, Tovo-Rodrigues L, Davey Smith G, Horta BL.  
701 Body mass index and psychiatric disorders: a Mendelian randomization study. *Scientific  
702 Reports* 2016; **6**(1): 32730.

703

- 704 40. van den Broek N, Treur JL, Larsen JK, Verhagen M, Verweij KJH, Vink JM. Causal  
705 associations between body mass index and mental health: a Mendelian randomisation  
706 study. *Journal of Epidemiology and Community Health* 2018; **72**(8): 708.
- 707
- 708 41. Vogelzangs N, Beekman AT, Boelhouwer IG, Bandinelli S, Milaneschi Y, Ferrucci L,  
709 Penninx BW. Metabolic depression: a chronic depressive subtype? Findings from the  
710 InCHIANTI study of older persons. *J Clin Psychiatry* 2011; **72**(5): 598-604.
- 711
- 712 42. Nigatu YT, Bültmann U, Reijneveld SA. The prospective association between obesity and  
713 major depression in the general population: does single or recurrent episode matter? *BMC*  
714 *Public Health* 2015; **15**(1): 350.
- 715
- 716 43. Grigolon RB, Trevizol AP, Gerchman F, Bambokian AD, Magee T, McIntyre RS *et al.* Is  
717 Obesity A Determinant Of Success With Pharmacological Treatment For Depression? A  
718 Systematic Review, Meta-Analysis And Meta-Regression. *Journal of Affective Disorders*  
719 2021; **287**: 54-68.
- 720
- 721 44. McQueen MJ, Hawken S, Wang X, Ounpuu S, Sniderman A, Probstfield J *et al.* Lipids,  
722 lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries  
723 (the INTERHEART study): a case-control study. *The Lancet* 2008; **372**(9634): 224-233.
- 724
- 725 45. Ulloque-Badaracco JR, Al-kassab-Córdova A, Hernandez-Bustamante EA, Alarcon-Braga  
726 EA, Huayta-Cortez M, Carballo-Tello XL *et al.* Association of apolipoproteins and  
727 lipoprotein(a) with metabolic syndrome: a systematic review and meta-analysis. *Lipids in*  
728 *Health and Disease* 2023; **22**(1): 98.
- 729

- 730 46. Juonala M, Viikari JSA, Kähönen M, Solakivi T, Helenius H, Jula A *et al.* Childhood Levels  
731 of Serum Apolipoproteins B and A-I Predict Carotid Intima-Media Thickness and Brachial  
732 Endothelial Function in Adulthood: The Cardiovascular Risk in Young Finns Study. *Journal*  
733 *of the American College of Cardiology* 2008; **52**(4): 293-299.
- 734
- 735 47. Ojanen X, Cheng R, Törmäkangas T, Rappaport N, Wilmanski T, Wu N *et al.* Towards early  
736 risk biomarkers: serum metabolic signature in childhood predicts cardio-metabolic risk in  
737 adulthood. *eBioMedicine* 2021; **72**.
- 738
- 739 48. González-González JG, Violante-Cumpa JR, Zambrano-Lucio M, Burciaga-Jimenez E,  
740 Castillo-Morales PL, Garcia-Campa M *et al.* HOMA-IR as a predictor of Health Outcomes  
741 in Patients with Metabolic Risk Factors: A Systematic Review and Meta-analysis. *High*  
742 *Blood Pressure & Cardiovascular Prevention* 2022; **29**(6): 547-564.
- 743
- 744 49. Harris WS, von Schacky C. The Omega-3 Index: a new risk factor for death from coronary  
745 heart disease? *Preventive Medicine* 2004; **39**(1): 212-220.
- 746
- 747 50. Harris WS, Tintle NL, Etherton MR, Vasan RS. Erythrocyte long-chain omega-3 fatty acid  
748 levels are inversely associated with mortality and with incident cardiovascular disease: The  
749 Framingham Heart Study. *Journal of Clinical Lipidology* 2018; **12**(3): 718-727.e716.
- 750
- 751 51. Kaikkonen JE, Jula A, Viikari JSA, Juonala M, Hutri-Kähönen N, Kähönen M *et al.*  
752 Associations of Serum Fatty Acid Proportions with Obesity, Insulin Resistance, Blood  
753 Pressure, and Fatty Liver: The Cardiovascular Risk in Young Finns Study. *The Journal of*  
754 *Nutrition* 2021; **151**(4): 970-978.
- 755



- 756 52. Harris WS, Pottala JV, Lacey SM, Vasani RS, Larson MG, Robins SJ. Clinical correlates  
757 and heritability of erythrocyte eicosapentaenoic and docosahexaenoic acid content in the  
758 Framingham Heart Study. *Atherosclerosis* 2012; **225**(2): 425-431.
- 759
- 760 53. Stark KD, Van Elsland ME, Higgins MR, Weatherford CA, Salem N. Global survey of the  
761 omega-3 fatty acids, docosahexaenoic acid and eicosapentaenoic acid in the blood stream  
762 of healthy adults. *Progress in Lipid Research* 2016; **63**: 132-152.
- 763
- 764 54. de Groot RHM, Emmett R, Meyer BJ. Non-dietary factors associated with n-3 long-chain  
765 PUFA levels in humans – a systematic literature review. *British Journal of Nutrition* 2019;  
766 **121**(7): 793-808.
- 767
- 768 55. Wang JQ, Mao L. The ERK Pathway: Molecular Mechanisms and Treatment of Depression.  
769 *Molecular Neurobiology* 2019; **56**(9): 6197-6205.
- 770
- 771 56. Duman CH, Schlesinger L, Kodama M, Russell DS, Duman RS. A Role for MAP Kinase  
772 Signaling in Behavioral Models of Depression and Antidepressant Treatment. *Biological*  
773 *Psychiatry* 2007; **61**(5): 661-670.
- 774
- 775 57. Duman RS, Voleti B. Signaling pathways underlying the pathophysiology and treatment of  
776 depression: novel mechanisms for rapid-acting agents. *Trends in Neurosciences* 2012;  
777 **35**(1): 47-56.
- 778
- 779 58. Zhang X, Yeung DCY, Karpisek M, Stejskal D, Zhou Z-G, Liu F *et al.* Serum FGF21 Levels  
780 Are Increased in Obesity and Are Independently Associated With the Metabolic Syndrome  
781 in Humans. *Diabetes* 2008; **57**(5): 1246-1253.
- 782

- 783 59. Kralisch S, Tönjes A, Krause K, Richter J, Lossner U, Kovacs P *et al.* Fibroblast growth  
784 factor-21 serum concentrations are associated with metabolic and hepatic markers in  
785 humans. *Journal of Endocrinology* 2013; **216**(2): 135-143.
- 786
- 787 60. Semba RD, Sun K, Egan JM, Crasto C, Carlson OD, Ferrucci L. Relationship of Serum  
788 Fibroblast Growth Factor 21 with Abnormal Glucose Metabolism and Insulin Resistance:  
789 The Baltimore Longitudinal Study of Aging. *The Journal of Clinical Endocrinology &*  
790 *Metabolism* 2012; **97**(4): 1375-1382.
- 791
- 792 61. Chen C, Cheung BMY, Tso AWK, Wang Y, Law LSC, Ong KL *et al.* High Plasma Level of  
793 Fibroblast Growth Factor 21 Is an Independent Predictor of Type 2 Diabetes: A 5.4-year  
794 population-based prospective study in Chinese subjects. *Diabetes Care* 2011; **34**(9): 2113-  
795 2115.
- 796
- 797 62. Li H, Fang Q, Gao F, Fan J, Zhou J, Wang X *et al.* Fibroblast growth factor 21 levels are  
798 increased in nonalcoholic fatty liver disease patients and are correlated with hepatic  
799 triglyceride. *Journal of Hepatology* 2010; **53**(5): 934-940.
- 800
- 801 63. Ciuculete DM, Voisin S, Kular L, Welihinda N, Jonsson J, Jagodic M *et al.* Longitudinal  
802 DNA methylation changes at MET may alter HGF/c-MET signalling in adolescents at risk  
803 for depression. *Epigenetics* 2020; **15**(6-7): 646-663.
- 804
- 805 64. Teixeira AL, Gama CS, Rocha NP, Teixeira MM. Revisiting the Role of Eotaxin-1/CCL11 in  
806 Psychiatric Disorders. *Frontiers in Psychiatry* 2018; **9**.
- 807

- 808 65. Erickson MA, Morofuji Y, Owen JB, Banks WA. Rapid Transport of CCL11 across the  
809 Blood-Brain Barrier: Regional Variation and Importance of Blood Cells. *Journal of*  
810 *Pharmacology and Experimental Therapeutics* 2014; **349**(3): 497.
- 811
- 812 66. Villeda SA, Luo J, Mosher KI, Zou B, Britschgi M, Bieri G *et al.* The ageing systemic milieu  
813 negatively regulates neurogenesis and cognitive function. *Nature* 2011; **477**(7362): 90-94.
- 814
- 815 67. Teixeira AL, Reis HJ, Nicolato R, Brito-Melo G, Correa H, Teixeira MM, Romano-Silva MA.  
816 Increased serum levels of CCL11/eotaxin in schizophrenia. *Progress in Neuro-*  
817 *Psychopharmacology and Biological Psychiatry* 2008; **32**(3): 710-714.
- 818
- 819 68. Grassi-Oliveira R, Brieztke E, Teixeira A, Pezzi JC, Zanini M, Lopes RP, Bauer ME.  
820 Peripheral chemokine levels in women with recurrent major depression with suicidal  
821 ideation. *Revista Brasileira de Psiquiatria* 2012; **34**(1): 71-75.
- 822
- 823 69. Panizzutti B, Gubert C, Schuh AL, Ferrari P, Bristot G, Fries GR *et al.* Increased serum  
824 levels of eotaxin/CCL11 in late-stage patients with bipolar disorder: An accelerated aging  
825 biomarker? *Journal of Affective Disorders* 2015; **182**: 64-69.
- 826
- 827 70. Simon NM, McNamara K, Chow CW, Maser RS, Papakostas GI, Pollack MH *et al.* A  
828 detailed examination of cytokine abnormalities in Major Depressive Disorder. *European*  
829 *Neuropsychopharmacology* 2008; **18**(3): 230-233.
- 830
- 831 71. Leighton SP, Nerurkar L, Krishnadas R, Johnman C, Graham GJ, Cavanagh J.  
832 Chemokines in depression in health and in inflammatory illness: a systematic review and  
833 meta-analysis. *Molecular Psychiatry* 2018; **23**(1): 48-58.
- 834

- 835 72. Goldsmith DR, Rapaport MH, Miller BJ. A meta-analysis of blood cytokine network  
836 alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder  
837 and depression. *Molecular Psychiatry* 2016; **21**(12): 1696-1709.
- 838
- 839 73. Osimo EF, Pillinger T, Rodriguez IM, Khandaker GM, Pariante CM, Howes OD.  
840 Inflammatory markers in depression: A meta-analysis of mean differences and variability in  
841 5,166 patients and 5,083 controls. *Brain, Behavior, and Immunity* 2020; **87**: 901-909.
- 842
- 843 74. Foley ÉM, Parkinson JT, Mitchell RE, Turner L, Khandaker GM. Peripheral blood cellular  
844 immunophenotype in depression: a systematic review and meta-analysis. *Molecular*  
845 *Psychiatry* 2023; **28**(3): 1004-1019.
- 846
- 847 75. Fernandes BS, Salagre E, Enduru N, Grande I, Vieta E, Zhao Z. Insulin resistance in  
848 depression: A large meta-analysis of metabolic parameters and variation. *Neuroscience &*  
849 *Biobehavioral Reviews* 2022; **139**: 104758.
- 850
- 851 76. Davyson E, Shen X, Gadd DA, Bernabeu E, Hillary RF, McCartney DL *et al.* Metabolomic  
852 Investigation of Major Depressive Disorder Identifies a Potentially Causal Association With  
853 Polyunsaturated Fatty Acids. *Biological Psychiatry* 2023.
- 854
- 855 77. Perry BI, Oltean BP, Jones PB, Khandaker GM. Cardiometabolic risk in young adults with  
856 depression and evidence of inflammation: A birth cohort study. *Psychoneuroendocrinology*  
857 2020; **116**: 104682.
- 858
- 859 78. Bolck A, Croon M, Hagenaars J. Estimating Latent Structure Models with Categorical  
860 Variables: One-Step Versus Three-Step Estimators. *Political Analysis* 2004; **12**(1): 3-27.
- 861



863 **Figure Legends**

864

865 **Figure 1. Predicted Marginal Mean Depressive Symptom Trajectories from Childhood to**  
866 **Early Adulthood in the ALSPAC Cohort**

867 Lines showing predicted marginal mean depressive symptom trajectories with shaded areas  
868 representing 95% confidence intervals.

869

870 **Figure 2. Volcano Plots Showing Differential Immune Protein Abundance Levels in**  
871 **Depressive Symptom Trajectories**

872 Panels **a** and **b** show results from basic and adjusted models respectively. The reference group  
873 for all analyses is the low-stable trajectory.

874 Abbreviations: 4E-BP1 – eukaryotic translation initiation factor; CCL11 – eotaxin-1; CCL25 – C-C  
875 motif chemokine 25; CDCP1 – CUB domain-containing protein 1; FGF-19 – fibroblast growth  
876 factor 19; FGF-21 – fibroblast growth factor 21; HGF – hepatic growth factor

877

878 **Figure 3. Volcano Plots Showing Differential Metabolite Abundance Levels in Depressive**  
879 **Symptom Trajectories**

880 Panels **a** and **b** show results from basic and adjusted models respectively. The reference group  
881 for all analyses is the low-stable trajectory. Orange points indicate upregulation and blue points  
882 indicate downregulation.

883 Abbreviations: ApoB/ApoA1 – apolipoprotein B to apolipoprotein A1 ratio, DHA/FA –  
884 docosahexaenoic acid to total fatty acids ratio, MUFA/FA – monounsaturated fatty acids to total  
885 fatty acids ratio, Omega-3/FA – omega-3 fatty acids to total fatty acids ratio, PUFA/FA –  
886 polyunsaturated fatty acids/total fatty acids ratio


887

888 **Figure 4. Differential Levels of Full Blood Count and Clinical Biochemistry Biomarkers in**  
889 **Different Depressive Symptom Trajectories**



890 Dot-and-whisker plots showing effect estimates and 95% confidence intervals for each biomarker.



891 The effect estimates and 95% confidence intervals from the models have been back-transformed


892 into their original scale for ease of interpretation; effect estimates represent the percentage  
893 difference in mean levels of each biomarker for respective trajectory, in relation to the low-stable  
894 trajectory (reference group). Panels a and b show results from basic and adjusted models  
895 respectively. Asterisks indicate evidence for the association after FDR correction of p-values.  
896 Abbreviations: WBC – white blood count, RBC – red blood count, Hb – haemoglobin, Hct –  
897 haematocrit, MCV – mean cell volume, MCH – mean cell haemoglobin, MCHC – mean  
898 corpuscular haemoglobin concentration, HOMA-IR – Homeostatic Model Assessment for Insulin  
899 Resistance, HDL – high-density lipoprotein, LDL – low-density lipoprotein, VLDL – very low-  
900 density lipoprotein, CRP – C-reactive protein, GGT – gamma-glutamyl transpeptidase, ALT –  
901 alanine aminotransferase, AST – aspartate aminotransferase, P3NP – procollagen-3 N-terminal  
902 peptide





**a****b**

**a****b**

**a****b**